Gut bacteria are to blame for the failure of immune checkpoint therapy for ovarian cancer, new research reveals.

The DeGregorio Family Foundation with support from the Torrey Coast Foundation Gastro Esophageal Investigator Network Initiative (GEMINI) has awarded $450,000 to Saar Gill, MD, PhD, of the University ...

Exploratory outcome measures include health-related quality of life, overall survival, and biomarker assessments. A broad cross-section of geographically and socioeconomically diverse clinical sites ...

Results also show that reducing the Padcev dose at treatment initiation may benefit older patients with urothelial carcinoma, ...

AstraZeneca's Imfinzi perioperative regimen improved survival outcomes in muscle-invasive bladder cancer, with FDA Priority ...

Results from a new study published in Clinical and Translational Immunology found that dual-target antibody therapy can enhance cancer-fighting T cells more effectively than current single-target ...

A team of researchers has developed a "gut-on-chip" (a miniature model of the human intestine on a chip-sized device) capable ...

AstraZeneca (AZN) has reported positive results from an analysis of its NIAGARA Phase 3 study of Imfinzi in the treatment of ...

Enfortumab vedotin with or without pembrolizumab offers disease control benefits for patients with upper tract urothelial cancer, said Evangelia Vlachou, MD, of Johns Hopkins Medicine.

An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic ...

It is a useful therapy with several drawbacks that limit its effectiveness, including prolonged light sensitivity, poor ...

Patient perceptions about their treatment for muscle-invasive bladder cancer (MIBC) over the last decade. Dr. Chowdhury began his presentation by emphasizing that muscle-invasive bladder cancer (MIBC) ...